Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Maxim resumes coverage of Moleculin Biotech at buy; PT $3

Maxim Group resumed coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.11 on June 5. On May 1, the SEC suspended trading in Moleculin, citing questions about the...

June 8, 2020

Markets

Brookline starts Assertio Holdings at buy; PT $3.50

Brookline Capital Markets launched coverage of Assertio Holdings (NASDAQ:ASRT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 2. Assertio is a pharmaceutical company that recently...

June 3, 2020

Markets

HCW starts Allena Pharma at buy; PT $10

H.C. Wainwright launched coverage of Allena Pharmaceuticals (NASDAQ:ALNA) with a “buy” rating and $10 price target. The stock closed at $1.68 on May 29. Allena is developing reloxaliase, an orally administered enzyme...

June 1, 2020

Markets

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

May 29, 2020

Markets

Analysts up Mersana Therapeutics PT to $21

Analysts for SVB Leerink and BTIG raised their price targets for Mersana Therapeutics (NASDAQ:MRSN) to $21 from $12 and $14, respectively, citing positive interim data from the expansion portion of the company’s Phase 1...

May 27, 2020

Markets

Brookline starts CohBar at buy; PT $10

Brookline Capital Markets initiated coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and $10 price target. The stock closed at $2.63 on May 26. CohBar is developing CB4211, a novel and optimized analog of MOTS-c, a...

May 27, 2020

Markets

Analysts start coverage of Lyra Therapeutics at buy, OP

Analysts for BTIG and William Blair launched coverage of Lyra Therapeutics (NASDAQ:LYRA) with “buy” and “outperform” ratings, respectively. Lyra is developing a novel drug delivery platform for ear, nose and throat...

May 26, 2020

Markets

HCW ups CymaBay Therapeutics to buy; PT $9

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral,” with a price target of $9, citing a possible lifting of the clinical hold on seladelpar development in liver disease. The stock closed...

May 26, 2020

Markets

Dawson James starts Sorrento Therapeutics at buy; PT $24

Dawson James Securities launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $24 price target. The stock closed at $5.07 on May 22. Analyst Jason Kolbert writes that Sorrento’s STI-1499...

May 26, 2020

Markets

Brookline starts Caladrius Biosciences at buy; PT $7

Brookline Capital Markets initiated coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and a price target of $7. The stock was quoted at $2.05, up 12 cents, at mid-day on May 22...

May 22, 2020

Markets

Raymond James adds Profound Medical to “analyst current favorite”

Raymond James added Profound Medical (TSX:PRN; NASDAQ:PROF) as an “analyst current favorite,” maintaining a “strong buy” recommendation, after AstraZeneca and Merck received FDA approval for their PARP inhibitor drug...

May 22, 2020

Markets

Brookline starts Cyclacel Pharma at buy; PT $22

Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...

May 19, 2020

Markets

Maxim ups Onconova Therapeutics to buy; PT $1.25

Maxim Group upgraded Onconova Therapeutics (NASDAQ:ONTX) to “buy” from “hold” with a new price target of $1.25, citing a strengthened balance sheet, and a sufficient cash runway into the third quarter of 2021, well past...

May 15, 2020

Markets

Brookline starts Biocept at buy; PT $2.06

Brookline Capital Markets initiated coverage of Biocept (NASDAQ:BIOC) with a “buy” rating and price target of $2.06. The stock closed at 44 cents on May 13. Biocept is a molecular oncology diagnostics company that...

May 14, 2020

Markets

SVB Leerink slashes Genfit PT to $20 from $50

SVB Leerink slashed its price target for Genfit (NASDAQ:GNFT) to $20 from $50, but maintained its “outperform” rating, citing topline interim Phase 3 results that showed elafibranor failed to demonstrate a statistically...

May 12, 2020

Markets

HCW halves Aimmune Therapeutics PT to $15 from $30

H.C. Wainwright halved its price target for Aimmune Therapeutics (NASDAQ:AIMT) to $30 from $15, and reiterated its “neutral” rating, citing the pandemic’s impact on the launch of Palforzia, the first drug treatment of...

May 12, 2020

Markets

BTIG cuts Endologix to neutral; removes price target

BTIG downgraded Endologix (NASDAQ:ELGX) to “neutral” without a price target, citing “greater uncertainty” that the potential COVID-19 impact on revenue could put the company’s financial covenants in peril. The stock...

May 12, 2020

Markets

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

May 12, 2020

Markets

HCW ups Pulse Biosciences PT to $16 from $6

H.C. Wainwright raised its price target for Pulse Biosciences (NASDAQ:PLSE) to $16 from $6, citing the company’s agreement with the FDA on requirements for a 510(k) submission for a general dermatological indication of...

May 12, 2020

Markets

Brookline doubles Arcturus Therapeutics PT to $64 from $32

Brookline Capital Markets raised its price target for Arcturus Therapeutics (NASDAQ:ARCT) to $64 from $32, citing positive immunogenicity data for its COVID-19 vaccine. The stock was quoted at $44.88, up $5.65, in...

May 11, 2020

Markets

HCW starts Precigen at buy; PT $5

H.C. Wainwright initiated coverage of Precigen (NASDAQ:PGEN) with a “buy” rating and $5 price target. The stock closed at $3.17 on May 7. Precigen, previously known as Intrexon, is focused on applying synthetic biology...

May 8, 2020

Markets

SVB Leerink starts Compugen at OP; PT $15

SVB Leerink launched coverage of Compugen (NASDAQ:CGEN) with an “outperform” rating and $15 price target. The stock closed at $13.22 on May 6. “TIGIT / PVRIG could be the next evolution in immune checkpoint blockade...

May 7, 2020

Subscribe